+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Self-monitoring Blood Glucose Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 5176270
  • Report
  • August 2020
  • Region: Global
  • 105 pages
  • Mordor Intelligence
UP TO OFF
until Dec 31st 2020

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott
  • Acon
  • Agamatrix Inc.
  • Arkray
  • Ascensia
  • Bionime Corporation
  • MORE
The Self-monitoring Blood Glucose market is expected to register a CAGR of over 8% during the forecast period (2020-2025), and the market is estimated to reach around USD 15 billion by 2025. The main diagnosis for diabetes patients is imbalances in blood glucose levels, which are not in compliance with the standard blood glucose levels. The general lab diagnostic tests can only help to diagnose the disease by the physicians. The patients with more fluctuations in glucose levels need to get it checked every day. Patients administering insulin need to check their blood glucose levels frequently, in order to adjust the doses of insulin or change the medication if necessary, which is only possible with the use of self-monitoring blood glucose devices. According to the National Mortality Database, diabetes contributed to over 17,000 deaths in 2017 (11% of all deaths). Diabetes was the underlying cause of death in around 4,800 deaths (28% of diabetes deaths). It was an associated cause of death in further 12,200 deaths (72% of diabetes deaths). According to the ADA (American Diabetes Association), the total assessed cost for diagnosed diabetes in 2018 was around USD 333 billion, which was inclusive of USD 242 billion in direct medical costs and USD 91 billion in augmented productivity. The increasing number of diabetes patients globally, growing awareness regarding the benefits of using self-monitoring devices, and the technological advancement in SMBG are some of the major factors supporting the growth of the Self-monitoring Blood Glucose market.

Key Market Trends

Most of the SMBG Market Revenue is generated from Blood Glucose Test Strips

The Glucometer is a one-time purchase. However, test strips, on the other hand, are a continuous investment, as a test strip needs to be disposed of after one use. However, test strips, on the other hand, are considered to be a continuous investment. Thus, it presents a considerable cost impact to the consumers. Overall, the global demand for blood glucose test strips is projected to witness significant growth over the forecast period. The growth of the market studied is expected to be spurred by the rising global diabetic population. The growth in market volumes and share of the test strip is expected to be better than that of glucometers, because of the difference in the use-case frequency. While an average glucose meter lasts anywhere between six months and three years, presenting a one-time cost, during the same time frame, the corresponding use of multiple (in the range of thousands) test strips may occur, causing a recurrent cost impact.

North America will Continue to Have the Largest Market Share During the Forecast Period

By the end of 2019, North America accounted for 12% of the total diabetes population and 6% of total type-1 diabetes patients. The prevalence of diabetes has increased dramatically during the past two decades, which is a fact-driven by the increased prevalence of obesity and lifestyle changes. It is estimated that North America has 22% of the worldwide obesity population. There is more carbohydrate consumption among the countries in the region, which is also one of the leading causes of obesity. In North America, the US is one of the countries with fast-growing chronic diseases and is the largest demand generating country for Self-monitoring Blood Glucose Devices.

Competitive Landscape

The global self-monitoring blood glucose market is consolidated, with few major manufacturers having a global market presence and occupy a major share, while the remaining manufacturers confine to the other local or region-specific manufacturers. Mergers and acquisitions that occurred between the players in the recent past helped the companies to strengthen their market presence. Panasonic acquired Bayer’s diabetes care unit and named it as Ascensia diabetes care, which continued its operations all over the world.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • Acon
  • Agamatrix Inc.
  • Arkray
  • Ascensia
  • Bionime Corporation
  • MORE
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 Self-monitoring blood glucose devices
5.1.1 By Component (Value, and Volume, 2012-2025)
5.1.1.1 Glucometer Devices
5.1.1.2 Test Strips
5.1.1.3 Lancets
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value, and Volume, 2012-2025)
5.2.1.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.1.2 Canada (Value, and Volume, 2012-2025)
5.2.1.2.1 By Component (Glucometer Devices, Test Strips, Lancets)
5.2.1.3 Rest of North America (Value, and Volume, 2012-2025)
5.2.1.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.2 Europe
5.2.2.1 France (Value, and Volume, 2012-2025)
5.2.2.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.2.2 Germany (Value, and Volume, 2012-2025)
5.2.2.2.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.2.3 Italy (Value, and Volume, 2012-2025)
5.2.2.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.2.4 Spain (Value, and Volume, 2012-2025)
5.2.2.4.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.2.5 United Kingdom (Value, and Volume, 2012-2025)
5.2.2.5.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.2.6 Russia (Value, and Volume, 2012-2025)
5.2.2.6.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.2.7 Rest of Europe (Value, and Volume, 2012-2025)
5.2.2.7.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.3 Latin America
5.2.3.1 Mexico (Value, and Volume, 2012-2025)
5.2.3.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.3.2 Brazil (Value, and Volume, 2012-2025)
5.2.3.2.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.3.3 Rest of Latin America (Value, and Volume, 2012-2025)
5.2.3.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4 Asia-Pacific
5.2.4.1 Japan (Value, and Volume, 2012-2025)
5.2.4.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.2 South Korea (Value, and Volume, 2012-2025)
5.2.4.2.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.3 China (Value, and Volume, 2012-2025)
5.2.4.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.4 India (Value, and Volume, 2012-2025)
5.2.4.4.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.5 Australia (Value, and Volume, 2012-2025)
5.2.4.5.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.6 Vietnam (Value, and Volume, 2012-2025)
5.2.4.6.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.7 Malaysia (Value, and Volume, 2012-2025)
5.2.4.7.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.8 Indonesia (Value, and Volume, 2012-2025)
5.2.4.8.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.9 Philippines (Value, and Volume, 2012-2025)
5.2.4.9.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.10 Thailand (Value, and Volume, 2012-2025)
5.2.4.10.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.4.11 Rest of Asia-Pacific (Value, and Volume, 2012-2025)
5.2.4.11.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.5 Middle-East and Africa
5.2.5.1 Saudi Arabia (Value, and Volume, 2012-2025)
5.2.5.1.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.5.2 Iran (Value, and Volume, 2012-2025)
5.2.5.2.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.5.3 Egypt (Value, and Volume, 2012-2025)
5.2.5.3.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.5.4 Oman (Value, and Volume, 2012-2025)
5.2.5.4.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.5.5 South Africa (Value, and Volume, 2012-2025)
5.2.5.5.1 By Component (Glucometer Devices, Test Strips, and Lancets)
5.2.5.6 Rest of Middle-East and Africa (Value, and Volume, 2012-2025)
5.2.5.6.1 By Component (Glucometer Devices, Test Strips, and Lancets)

6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2025)
6.2 Type-2 Diabetes Population (2012-2025)

7 COMPETITIVE LANDSCAPE
7.1 Vendor Market Share
7.2 Company Profiles
7.2.1 Abbott
7.2.2 F. Hoffmann-La Roche AG
7.2.3 Johnson & Johnson
7.2.4 Arkray
7.2.5 Ascensia
7.2.6 Agamatrix Inc.
7.2.7 Bionime Corporation
7.2.8 Acon
7.2.9 Medisana
7.2.10 Trivida
7.2.11 Rossmax

8 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown

Loading
LOADING...

  • Abbott
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Arkray
  • Ascensia
  • Agamatrix Inc.
  • Bionime Corporation
  • Acon
  • Medisana
  • Trivida
  • Rossmax
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll